Decreased pulmonary vasoreactivity in an animal model of chronic Pseudomonas pneumonia

Am Rev Respir Dis. 1990 Jul;142(1):221-9. doi: 10.1164/ajrccm/142.1.221.

Abstract

Chronic pulmonary infection/colonization caused by Pseudomonas aeruginosa accounts for much of the morbidity and mortality in cystic fibrosis (CF). The effect of chronic pulmonary P. aeruginosa infection on the pulmonary circulation has not been studied. Therefore, we investigated the effect of chronic P. aeruginosa infection on pulmonary hemodynamics in a rat model. Two groups of rats were inoculated with either agar beads containing 1.0 x 10(4) colony-forming units of P. aeruginosa (infected) or an equal volume of sterile beads alone (control). In vivo, pulmonary vasoreactivity measured as the percent change in total pulmonary resistance during hypoxia was decreased at 1 wk (22 +/- 7% versus 57 +/- 3%), 2 wk (29 +/- 5% versus 73 +/- 17%), 3 wk (41 +/- 8% versus 77 +/- 14%), and 6 to 9 wk (23 +/- 10 versus 53 +/- 7; p less than 0.05 all time points; mean +/- SEM) postinoculation in infected animals when compared with that in time-matched control animals. At 6 to 9 wk postinoculation, pulmonary artery pressure was significantly elevated in infected rats (25.8 +/- 1.6 versus 21.0 +/- 1.0 mm Hg; p less than 0.05) when compared with that in control animals. Histopathologic findings were characterized by bronchiectasis as well as by chronic bronchial, parenchymal, and perivascular inflammation at all time points in infected animals.(ABSTRACT TRUNCATED AT 250 WORDS)

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 6-Ketoprostaglandin F1 alpha / analysis
  • Animals
  • Lung / analysis
  • Male
  • Pneumonia / etiology*
  • Pneumonia / physiopathology
  • Pseudomonas Infections / physiopathology*
  • Pulmonary Circulation / physiology*
  • Pulmonary Wedge Pressure / physiology
  • Rats
  • Rats, Inbred Strains
  • SRS-A / analysis
  • Thromboxane B2 / analysis

Substances

  • SRS-A
  • Thromboxane B2
  • 6-Ketoprostaglandin F1 alpha